U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H15NO3.ClH.H2O
Molecular Weight 275.729
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROCOTARNINE HYDROCHLORIDE MONOHYDRATE

SMILES

O.Cl.COC1=C2OCOC2=CC3=C1CN(C)CC3

InChI

InChIKey=ZNQOHJRIIMHFDR-UHFFFAOYSA-N
InChI=1S/C12H15NO3.ClH.H2O/c1-13-4-3-8-5-10-12(16-7-15-10)11(14-2)9(8)6-13;;/h5H,3-4,6-7H2,1-2H3;1H;1H2

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C12H15NO3
Molecular Weight 221.2524
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/19252340

Hydrocotarnine is a crystalline alkaloid, obtained from opium and also formed by the reduction of cotarnine. It is a non-narcotic opium alkaloid. Hydrocotarnine is supposed to potentiate the analgesic effect of oxycodone with unknown mechanism.

CNS Activity

CNS Penetrant
2554
Curator's Comment: The tests were performed at different time periods (5, 15, 45 and 120 min) after male and female Wistar rats were treated with seized heroin. Seized heroin contained a mixture of opiate alkaloids, including hydrocotarnine. Opiate alkaloids were quantitatively determined in brain regions known for their high concentration of µ-opiate receptors: cortex, brainstem, amygdala and basal ganglia. Human data not available.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 18.4 µM [IC50]
Inhibitor
8297
 6.63 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Unknown

Approved Use

Compound injection of oxycodone and hydrocotarnine is effective for cancer pain treatment
PubMed

PubMed

TitleDatePubMed
Determination of oxycodone and hydrocotarnine in cancer patient serum by high-performance liquid chromatography with electrochemical detection.
2005 Mar
Comparison of the various opiate alkaloid contaminants and their metabolites found in illicit heroin with 6-monoacetyl morphine as indicators of heroin ingestion.
2006 May
[Conversion ratio between intravenous oxycodone/hydrocotarnine and sustained-release oral oxycodone in patients with cancer pain].
2007 Dec
Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain.
2007 Nov
Effect of hydrocotarnine on cytochrome P450 and P-glycoprotein.
2009
[Efficacy and safety of continuous subcutaneous injection of the compound oxycodone in cancer pain management: the first 4-year audit].
2009 Oct
[Efficacy and safety of compound oxycodone injection for cancer pain relief-a multicenter survey of prescriptions].
2010 May
Patents

Patents

04769480
6
20030039699
8
20090269772
13
7192608
6

Sample Use Guides

In Vivo Use Guide
injections of oxycodone and hydrocotarnine contains 8 mg of oxycodone hydrochloride and 2 mg of hydrocotarnine hydrochloride.
Route of Administration: Other
In Vitro Use Guide
Hydrocotarnine (0.000388–38.8 mM) did not induce a significant change in the metabolic activities of CYP2C9, 2C19, and 2E1. Although weak inhibitory effects were observed on CYP3A4 and 2D6, the inhibition rate was less than 50% at the concentrations below 3.88 mM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:15:11 GMT 2023
Edited
by admin
on Sat Dec 16 01:15:11 GMT 2023
Record UNII
4301VZ4T43
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDROCOTARNINE HYDROCHLORIDE MONOHYDRATE
MI   WHO-DD  
Common Name English
HYDROCOTARNINE HYDROCHLORIDE HYDRATE
JAN  
Common Name English
HYDROCOTARNINE HYDROCHLORIDE HYDRATE [JAN]
Common Name English
HYDROCOTARNINE HYDROCHLORIDE
Common Name English
8-METHOXY-5,6-METHYLENEDIOXY-2-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE HYDROCHLORIDE MONOHYDRATE
Systematic Name English
1,3-DIOXOLO(4,5-G)ISOQUINOLINE, 5,6,7,8-TETRAHYDRO-4-METHOXY-6-METHYL-, HYDROCHLORIDE, HYDRATE (1:1:1)
Systematic Name English
5,6,7,8-TETRAHYDRO-4-METHOXY-6-METHYL-1,3-DIOXOLO(4,5-G)ISOQUINOLINE HYDROCHLORIDE HYDRATE
Systematic Name English
Hydrocotarnine hydrochloride monohydrate [WHO-DD]
Common Name English
HYDROCOTARNINE HYDROCHLORIDE MONOHYDRATE [MI]
Common Name English
5,6,7,8-TETRAHYDRO-4-METHOXY-6-METHYL-1,3-DIOXOLO(4,5-G)ISOQUINOLINE HYDROCHLORIDE MONOHYDRATE
Systematic Name English
Code System Code Type Description
FDA UNII
4301VZ4T43
Created by admin on Sat Dec 16 01:15:11 GMT 2023 , Edited by admin on Sat Dec 16 01:15:11 GMT 2023
PRIMARY
ChEMBL
CHEMBL1606295
Created by admin on Sat Dec 16 01:15:11 GMT 2023 , Edited by admin on Sat Dec 16 01:15:11 GMT 2023
PRIMARY
SMS_ID
100000166113
Created by admin on Sat Dec 16 01:15:11 GMT 2023 , Edited by admin on Sat Dec 16 01:15:11 GMT 2023
PRIMARY
PUBCHEM
11070
Created by admin on Sat Dec 16 01:15:11 GMT 2023 , Edited by admin on Sat Dec 16 01:15:11 GMT 2023
PRIMARY
EVMPD
SUB180103
Created by admin on Sat Dec 16 01:15:11 GMT 2023 , Edited by admin on Sat Dec 16 01:15:11 GMT 2023
PRIMARY
CAS
6078-54-2
Created by admin on Sat Dec 16 01:15:11 GMT 2023 , Edited by admin on Sat Dec 16 01:15:11 GMT 2023
PRIMARY
MERCK INDEX
m6095
Created by admin on Sat Dec 16 01:15:11 GMT 2023 , Edited by admin on Sat Dec 16 01:15:11 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID50209602
Created by admin on Sat Dec 16 01:15:11 GMT 2023 , Edited by admin on Sat Dec 16 01:15:11 GMT 2023
PRIMARY
Related Record Type Details
Structure of HYDROCOTARNINE
PARENT -> SALT/SOLVATE
Structure of HYDROCOTARNINE HYDROCHLORIDE ANHYDROUS
ANHYDROUS->SOLVATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966